GT Biopharma (GTBP) to Release Quarterly Earnings on Thursday

GT Biopharma (NASDAQ:GTBP) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 21, 2026 at 9:30 AM ET.

GT Biopharma (NASDAQ:GTBP) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03). On average, analysts expect GT Biopharma to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

GT Biopharma Trading Up 0.2%

Shares of GTBP opened at $0.32 on Tuesday. GT Biopharma has a twelve month low of $0.26 and a twelve month high of $1.78. The company has a market cap of $14.22 million, a P/E ratio of -0.05 and a beta of 0.90. The company’s fifty day simple moving average is $0.41 and its 200-day simple moving average is $0.43.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on GTBP shares. Wall Street Zen raised shares of GT Biopharma to a “hold” rating in a research note on Saturday, June 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of GT Biopharma in a research report on Wednesday, July 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, GT Biopharma has an average rating of “Sell”.

About GT Biopharma

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).